ePro

Electronic Solutions for Patient-Reported Data

Business & Finance, Management & Leadership, Management
Cover of the book ePro by Brian Tiplady, Taylor and Francis
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Brian Tiplady ISBN: 9781317141907
Publisher: Taylor and Francis Publication: May 13, 2016
Imprint: Routledge Language: English
Author: Brian Tiplady
ISBN: 9781317141907
Publisher: Taylor and Francis
Publication: May 13, 2016
Imprint: Routledge
Language: English

Patient self-reported data has become increasingly important in today's clinical trials. Trials in some disease indications rely upon patient recorded diary data as the primary endpoint to demonstrate drug efficacy - including, for example, indications such as insomnia, migraine and pain. In addition, improvements in quality of life measured using patient questionnaires can now be included as claims on drug labelling. Traditionally these data have been collected using paper questionnaires and diaries issued to subjects. Regulators and the industry have become increasingly aware of the limitations of recording patient reported outcomes data on paper including data quality and integrity issues. As a result there is a growing interest in collection of patient reported outcomes data using electronic means (ePRO). Solutions include handheld PDAs, Interactive Voice Response (IVR) systems, and other site-based hardware such as touchscreen PCs. Recently, there has been much open debate with the regulators around the use of ePRO in clinical drug submissions. US and European agencies have approved new drugs that have included ePRO data in the submission dossier, but there are many questions around the adoption of the technology that concern the community. These include: ¢ How should instruments developed on paper be adapted for electronic use, and what degree of validation should be done between paper and electronic forms? ¢ How can researchers ensure they are complying with regulatory requirements including the PRO guidance published by FDA in 2009 when using ePRO solutions? ¢ Can fewer patients be exposed in a clinical trial as a result of improved data quality obtained using electronic diaries? ¢ What type of solution should be used for certain patient populations and protocols, and how can ePRO solutions be designed optimally to increase patient acceptability and compliance? Bill Byrom and Brian Tiplady's ePro addresses all these issues, reviews the new FDA guidance, and provides a very contemporary view on this important subject.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Patient self-reported data has become increasingly important in today's clinical trials. Trials in some disease indications rely upon patient recorded diary data as the primary endpoint to demonstrate drug efficacy - including, for example, indications such as insomnia, migraine and pain. In addition, improvements in quality of life measured using patient questionnaires can now be included as claims on drug labelling. Traditionally these data have been collected using paper questionnaires and diaries issued to subjects. Regulators and the industry have become increasingly aware of the limitations of recording patient reported outcomes data on paper including data quality and integrity issues. As a result there is a growing interest in collection of patient reported outcomes data using electronic means (ePRO). Solutions include handheld PDAs, Interactive Voice Response (IVR) systems, and other site-based hardware such as touchscreen PCs. Recently, there has been much open debate with the regulators around the use of ePRO in clinical drug submissions. US and European agencies have approved new drugs that have included ePRO data in the submission dossier, but there are many questions around the adoption of the technology that concern the community. These include: ¢ How should instruments developed on paper be adapted for electronic use, and what degree of validation should be done between paper and electronic forms? ¢ How can researchers ensure they are complying with regulatory requirements including the PRO guidance published by FDA in 2009 when using ePRO solutions? ¢ Can fewer patients be exposed in a clinical trial as a result of improved data quality obtained using electronic diaries? ¢ What type of solution should be used for certain patient populations and protocols, and how can ePRO solutions be designed optimally to increase patient acceptability and compliance? Bill Byrom and Brian Tiplady's ePro addresses all these issues, reviews the new FDA guidance, and provides a very contemporary view on this important subject.

More books from Taylor and Francis

Cover of the book The Idea of Nation and its Future in India by Brian Tiplady
Cover of the book Teacher Appraisal by Brian Tiplady
Cover of the book Flight Catering by Brian Tiplady
Cover of the book Hans Mol and the Sociology of Religion by Brian Tiplady
Cover of the book The Content, Structure, and Operation of Thought Systems by Brian Tiplady
Cover of the book Youth Development in Football by Brian Tiplady
Cover of the book Misperceptions of the Social World by Brian Tiplady
Cover of the book The Myth of the Russian Intelligentsia by Brian Tiplady
Cover of the book Regulating Bodies by Brian Tiplady
Cover of the book On the Foundations of Happiness in Economics by Brian Tiplady
Cover of the book Understanding Educational Aims by Brian Tiplady
Cover of the book British Business in Post-Colonial Malaysia, 1957-70 by Brian Tiplady
Cover of the book Greek Tragedy by Brian Tiplady
Cover of the book Masculinity, Law and Family by Brian Tiplady
Cover of the book Education, Childhood and Anarchism by Brian Tiplady
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy